IL169316A - Small molecules modulate hepatocyte growth factor (dispersion factor) - Google Patents
Small molecules modulate hepatocyte growth factor (dispersion factor)Info
- Publication number
- IL169316A IL169316A IL169316A IL16931605A IL169316A IL 169316 A IL169316 A IL 169316A IL 169316 A IL169316 A IL 169316A IL 16931605 A IL16931605 A IL 16931605A IL 169316 A IL169316 A IL 169316A
- Authority
- IL
- Israel
- Prior art keywords
- factor
- activity
- small molecule
- hepatocyte growth
- molecule modulators
- Prior art date
Links
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 title 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 title 2
- 150000003384 small molecules Chemical class 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43553302P | 2002-12-21 | 2002-12-21 | |
| US10/740,708 US7192976B2 (en) | 2002-12-21 | 2003-12-18 | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| PCT/US2003/040917 WO2004058721A2 (en) | 2002-12-21 | 2003-12-19 | Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL169316A0 IL169316A0 (en) | 2007-07-04 |
| IL169316A true IL169316A (en) | 2013-09-30 |
Family
ID=32685400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL169316A IL169316A (en) | 2002-12-21 | 2005-06-21 | Small molecules modulate hepatocyte growth factor (dispersion factor) |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US7192976B2 (enExample) |
| EP (2) | EP2292227B1 (enExample) |
| JP (3) | JP5160019B2 (enExample) |
| CN (1) | CN1747730B (enExample) |
| AU (1) | AU2003301224C1 (enExample) |
| CA (1) | CA2511199C (enExample) |
| DK (2) | DK1572199T3 (enExample) |
| HU (1) | HUE030700T2 (enExample) |
| IL (1) | IL169316A (enExample) |
| WO (1) | WO2004058721A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US20110230407A1 (en) * | 2005-03-14 | 2011-09-22 | Alexander Yuzhakov | Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma |
| US7879898B1 (en) | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| EP2313093A4 (en) | 2008-07-10 | 2012-03-28 | Angion Biomedica Corp | METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY |
| US20110237633A1 (en) * | 2008-12-11 | 2011-09-29 | Bijoy Panicker | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| EP2493495A4 (en) * | 2009-07-10 | 2013-08-21 | Univ Northwestern | HERZSCHÜTZENDE ROLE OF LIVER CELLS AND SEKRETORIC FACTORS FROM LIVER CELLS IN MYOCARDIAN EMERGENCE |
| US20120190668A1 (en) * | 2009-08-12 | 2012-07-26 | Oehlen Lambertus J W M | Enhancement of cellular transplantation using small moleucle modulators of hepatocyte growth factor (scatter factor) activity |
| RU2639876C2 (ru) * | 2010-03-30 | 2017-12-25 | Версеон Корпорейшн | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина |
| WO2012047826A2 (en) | 2010-10-05 | 2012-04-12 | Angion Biomedica Corp. | Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| JP6173298B2 (ja) | 2011-04-02 | 2017-08-02 | ワシントン ステート ユニバーシティ | 治療薬としての肝細胞増殖因子模倣体 |
| US8754044B2 (en) | 2011-05-03 | 2014-06-17 | Northwestern University | Neuroprotection by hepatic cells and hepatocyte secretory factors |
| UY34200A (es) * | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3-(fluorovinil)pirazoles y su uso |
| US9951025B2 (en) | 2013-03-15 | 2018-04-24 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
| MX373964B (es) | 2013-03-15 | 2020-07-13 | Verseon Corp | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. |
| US10189810B2 (en) | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| SI3261639T1 (sl) | 2015-02-27 | 2023-01-31 | Verseon International Corporation | Substituirane pirazolne spojine kot zaviralci serinskih proteaz |
| CA3133803A1 (en) * | 2019-04-11 | 2020-10-15 | Angion Biomedica Corp. | Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole |
| WO2021087392A1 (en) * | 2019-10-31 | 2021-05-06 | Angion Biomedica Corp. | Improving renal function after kidney transplantation |
| WO2021183774A1 (en) * | 2020-03-12 | 2021-09-16 | Angion Biomedica Corp. | Treating acute respiratory distress |
| US20230372299A1 (en) * | 2020-10-14 | 2023-11-23 | Angion Biomedica Corp. | Preparation of terevalefim and formulations thereof |
| EP4236944A4 (en) * | 2020-11-02 | 2024-09-04 | Athira Pharma, Inc. | Bicyclic compounds and uses thereof for the treatment of diseases |
| WO2022217070A1 (en) * | 2021-04-09 | 2022-10-13 | Angion Biomedica Corp. | Hgf/sf mimetic compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE138770C (enExample) * | ||||
| JPS48713Y1 (enExample) | 1967-12-19 | 1973-01-09 | ||
| JPS48713U (enExample) | 1971-05-22 | 1973-01-08 | ||
| DD138770A1 (de) * | 1978-09-20 | 1979-11-21 | Juergen Liebscher | Verfahren zur herstellung von 5-styryl-pyrazolen und ihren vinylogen |
| JPH02193994A (ja) | 1989-01-23 | 1990-07-31 | Kyowa Hakko Kogyo Co Ltd | ピリダジノン誘導体 |
| FR2669633B1 (fr) * | 1990-11-23 | 1993-01-22 | Adir | Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5476076A (en) * | 1994-12-06 | 1995-12-19 | Zhou; Zhishan | Internal combustion piston engine utilizing interference movable fit technology |
| JPH11288112A (ja) | 1998-04-06 | 1999-10-19 | Mitsubishi Paper Mills Ltd | 電子写真感光体 |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| WO2001034650A1 (en) * | 1999-11-09 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services | Hgf-sf monoclonal antibody combinations |
| EP1355921A2 (en) | 2000-06-29 | 2003-10-29 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
| US6610726B2 (en) | 2001-06-29 | 2003-08-26 | North Shore-Long Island Jewish Research Institute | Compositions and agents for modulating cellular proliferation and angiogenesis |
| US6589997B2 (en) | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| AU2002313690A1 (en) | 2002-07-19 | 2004-02-09 | Targacept, Inc. | Five-membered heteroaromatic olefinic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of ncotinic cholinergic receptors |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
-
2003
- 2003-12-18 US US10/740,708 patent/US7192976B2/en not_active Expired - Lifetime
- 2003-12-19 CN CN2003801095507A patent/CN1747730B/zh not_active Expired - Fee Related
- 2003-12-19 JP JP2004563939A patent/JP5160019B2/ja not_active Expired - Fee Related
- 2003-12-19 EP EP10011181.4A patent/EP2292227B1/en not_active Expired - Lifetime
- 2003-12-19 AU AU2003301224A patent/AU2003301224C1/en not_active Ceased
- 2003-12-19 CA CA2511199A patent/CA2511199C/en not_active Expired - Lifetime
- 2003-12-19 HU HUE10011181A patent/HUE030700T2/en unknown
- 2003-12-19 DK DK03814306.1T patent/DK1572199T3/da active
- 2003-12-19 DK DK10011181.4T patent/DK2292227T3/en active
- 2003-12-19 WO PCT/US2003/040917 patent/WO2004058721A2/en not_active Ceased
- 2003-12-19 EP EP03814306.1A patent/EP1572199B1/en not_active Expired - Lifetime
-
2004
- 2004-12-29 US US11/025,373 patent/US7265112B2/en not_active Expired - Lifetime
- 2004-12-29 US US11/024,615 patent/US7250437B2/en not_active Expired - Lifetime
-
2005
- 2005-06-21 IL IL169316A patent/IL169316A/en active IP Right Grant
-
2007
- 2007-08-13 US US11/891,618 patent/US8580834B2/en not_active Expired - Fee Related
-
2010
- 2010-08-23 JP JP2010186703A patent/JP5755417B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-07 US US14/047,907 patent/US9663471B2/en not_active Expired - Fee Related
-
2015
- 2015-01-30 JP JP2015016424A patent/JP2015078246A/ja active Pending
-
2019
- 2019-01-11 US US16/245,373 patent/US20190382348A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL169316A (en) | Small molecules modulate hepatocyte growth factor (dispersion factor) | |
| DE69529670D1 (de) | Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen | |
| CO5271691A1 (es) | Nuevos compuestos | |
| WO2010005580A3 (en) | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
| AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| SE9904176D0 (sv) | New use | |
| TW200642685A (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
| SE9903544D0 (sv) | Novel compounds | |
| GEP20094723B (en) | Tetraazabenzo [e] azulene derivatives and analogs thereof | |
| CY1110631T1 (el) | Διαλυτοποιημενα δηλητηρια τοποϊσομερασης | |
| MY139446A (en) | Novel quinoline derivatives | |
| IS7102A (is) | Taxól-eflandi efnasambönd | |
| WO2003024955A3 (en) | Small molecule inhibitors of caspases | |
| SE9904508D0 (sv) | New compounds | |
| BR0210028A (pt) | Agentes antibacterianos | |
| SE0302192D0 (sv) | Novel compounds | |
| SE0400043D0 (sv) | New compounds | |
| MY135218A (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases | |
| YU87202A (sh) | Derivati arilmetilamina koji se koriste kao inhibitori triptaze | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| NO20020282D0 (no) | Nytt difenylpiperidinderivat | |
| SE9903997D0 (sv) | New compounds | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
| MXPA04001250A (es) | Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6). | |
| DE60202942D1 (de) | Thiazolopyrimidine und deren verwendung als modulatoren der chemokinrezeptoraktivität |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |